Discovers and develops targeted cancer therapies. Focuses on synthetic lethality to selectively kill cancer cells. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 67% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades 20% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 67% a year on average.
Sales run at $218.7M a year. A small number, but proof the product has real buyers.
There is $639.4M in the vault; even if every debt were paid off, $611.5M would remain.
A loss of $113.7M against $218.7M in annual sales.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 23/100.
Right now the product sells for less than it costs to make; every sale deepens the loss.
On our five-subject report card, IDYA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: IDYA is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (51/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.